CN Patent

CN106153797B — 一种依鲁替尼及依鲁替尼制剂有关物质分析方法

Assigned to Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd · Expires 2017-08-29 · 9y expired

What this patent protects

本发明属于药物合成领域。具体地，本发明涉及依鲁替尼(1‑[(3R)‑3‑[4‑氨基‑3‑(4‑苯氧基苯基)‑1H吡唑并[3，4‑d]嘧啶‑1‑基]‑1‑哌啶基]‑2‑丙烯‑1‑酮)制备过程中出现的杂质及对依鲁替尼制剂进行分析的方法。

USPTO Abstract

本发明属于药物合成领域。具体地，本发明涉及依鲁替尼(1‑[(3R)‑3‑[4‑氨基‑3‑(4‑苯氧基苯基)‑1H吡唑并[3，4‑d]嘧啶‑1‑基]‑1‑哌啶基]‑2‑丙烯‑1‑酮)制备过程中出现的杂质及对依鲁替尼制剂进行分析的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN106153797B
Jurisdiction
CN
Classification
—
Expires
2017-08-29
Drug substance claim
No
Drug product claim
No
Assignee
Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.